Article
Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
American journal of therapeutics - 1 Jan 2000
Bermúdez-Pirela Valmore, Souki Aida, Cano-Ponce Clímaco, Bermúdez-Arias Fernando, Mengual-Moreno Edgardo, Leal-Gonzalez Elliuz, Lemus-Antepaz Miguel, de Bravo Mayela Cabrera, de Díaz Anilsa Amell, de Pirela Nilka Leal, Cano-Peñaloza Raquel, Puche-Medina Guillermo, Arraiz Navlet, Reyna-Villazmil Nadia, Contreras Freddy, Israili Zafar H, Valasco Manuel
Abstract excerpt
OBJECTIVE: The combination of hypertriglyceridemia and low high density lipoprotein (HDL) cholesterol is one of the most common lipid abnormalities. Thus, the aim of this study was to determine the effects of ciprofibrate on lipid profile in patients with Frederickson's type IV dyslipidemia phenotype. RESEARCH DESIGN AND METHODS: Seventy-five patients with type IV dyslipidemia were assigned at random to 1 of 2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.